◀ Back to MTOR

MTOR — RAD52

Text-mined interactions from Literome

Boulay et al., Clin Cancer Res 2005 (Breast Neoplasms...) : RAD001 ( everolimus ), a mammalian target of rapamycin (mTOR) pathway inhibitor in phase II clinical trials in oncology, exerts potent antiproliferative/antitumor activities
Albert et al., Mol Cancer Ther 2006 (Breast Neoplasms) : Irradiation induced Akt and mTOR signaling , and this signaling is attenuated by RAD001
Rossi et al., Proc Natl Acad Sci U S A 2006 (Disease Models, Animal...) : Treatment with RAD001 ( everolimus ), an mTOR inhibitor , diminished the translational response and cell proliferation in tumor lesions, pointing to mTOR inhibition as a therapeutic approach for imatinib-resistant GIST
Haritunians et al., Leukemia 2007 (Lymphoma, Mantle-Cell) : As improved therapy for MCL is required and the mTOR pathway may be involved in its pathophysiology, the antiproliferative effects of RAD001 ( everolimus ), an mTOR inhibitor , against three MCL cell lines were investigated
Mabuchi et al., Cancer Res 2007 (Disease Models, Animal...) : In vivo effects of RAD001 on Akt-mTOR signaling , tumor cell proliferation, and blood vessel area were analyzed by immunohistochemistry and Western blot analysis
Xie et al., Int Immunol 2007 (Autoimmune Diseases...) : In addition, blocking this axis using RAD001 , an mTOR inhibitor , ameliorated lymphoproliferation and modulated serum IgG anti-nuclear auto-antibodies
Kim et al., Autophagy 2008 (Disease Models, Animal...) : To test this hypothesis, combinations of Z-DEVD ( caspase-3 inhibitor ), RAD001 ( mTOR inhibitor ) and irradiation were tested in cell and mouse models
Meikle et al., J Neurosci 2008 (Disease Models, Animal...) : We have tested rapamycin and RAD001 [ 40-O- ( 2-hydroxyethyl ) -rapamycin ], both mammalian target of rapamycin mTORC1 inhibitors , as potential therapeutic agents in this model ... We have tested rapamycin and RAD001 [ 40-O- ( 2-hydroxyethyl ) -rapamycin ], both mammalian target of rapamycin mTORC1 inhibitors , as potential therapeutic agents in this model
Schnell et al., Cancer Res 2008 (Mammary Neoplasms, Experimental...) : Because RAD001 , a specific mTOR allosteric inhibitor , was ineffective in the preceding experiments, we concluded that the effects observed for NVP-BEZ235 are in part driven by PI3K target modulation
Tam et al., Cancer Lett 2009 (Carcinoma, Hepatocellular...) : In vitro, HCC cell lines were exposed to RAD001 , an mTOR inhibitor , either alone or in combination with cisplatin
Wolpin et al., J Clin Oncol 2009 (Pancreatic Neoplasms) : We performed a multi-institutional, single-arm, phase II study of RAD001 ( everolimus ), an oral inhibitor of mTOR , in patients who experienced treatment failure on first-line therapy with gemcitabine
Breuleux et al., Mol Cancer Ther 2009 (Neoplasms) : RAD001 ( everolimus ), an mTORC1 ( mTOR/raptor ) inhibitor , has broad antitumor activity in preclinical models and cancer patients
Nishioka et al., Int J Cancer 2009 (Leukemia, Myeloid, Acute) : Our study explored the drug interaction of all-trans retinoic acid ( ATRA ) and RAD001 ( everolimus ), the inhibitor of mammalian target of rapamycin complex 1 ( mTORC1 ), in acute myelogenous leukemia ( AML ) NB4 and HL60 cells
Fujishita et al., Cell cycle (Georgetown, Tex.) 2009 (Adenoma...) : We have recently found that the mTORC1 pathway is activated in intestinal adenomas of Apc mutant mice, accompanied by an elevated level of mTOR protein, and that treatment with RAD001 , an mTORC1 inhibitor , suppresses the growth of these polyps
Yao et al., J Clin Oncol 2010 (Neuroendocrine Tumors...) : Everolimus ( RAD001 ), an oral inhibitor of mammalian target of rapamycin , in combination with octreotide has demonstrated encouraging antitumor activity in patients with NETs
Mancini et al., J Cell Biochem 2010 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : RAD 001 ( everolimus ) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia
Parikh et al., Leukemia & lymphoma 2010 (Diarrhea...) : Experience with everolimus ( RAD001 ), an oral mammalian target of rapamycin inhibitor , in patients with systemic mastocytosis ... We tested the efficacy of everolimus ( RAD001 ), a novel oral mTOR inhibitor , at a dose of 10 mg daily in an open label, non-comparative Phase II trial for patients with SM. Ten patients were enrolled from April 2007 to October 2008
Zatelli et al., Endocr Relat Cancer 2010 (Bronchial Neoplasms...) : It has been previously demonstrated that everolimus, or RAD001 , an mTOR inhibitor , has potent antiproliferative effects in human endocrine tumors
Moriceau et al., Cancer Res 2010 (Bone Neoplasms...) : In this study, we investigated in vivo the effects of RAD001 ( Everolimus ), a new orally available mTOR inhibitor , on the growth of human and mouse osteosarcoma cells either alone or in combination with zoledronate ( ZOL ), an anti-osteoporotic drug used to treat bone metastases
Pantaleo et al., J Exp Clin Cancer Res 2010 (Gastrointestinal Stromal Tumors) : Imatinib and nilotinib directly inhibit the kinase activity of KIT, while RAD001 ( everolimus ) inhibits mTOR
Lee et al., Mol Cancer Ther 2011 (Disease Models, Animal...) : Pituitary adenomas show activation of the PI3K/AKT/mTOR pathway, but only a fraction of them respond in vitro to the antiproliferative action of rapamycin and RAD001 ( mTOR inhibitors ), possibly because of the described negative feedback loop on AKT which reactivates the signaling cascade
Loehberg et al., Biochem Pharmacol 2012 (Breast Neoplasms...) : Chloroquine and RAD001 inhibited phosphorylation of mTOR and its downstream target, S6K1
Rosich et al., Clin Cancer Res 2012 (Lymphoma, Mantle-Cell) : The first clinical studies of everolimus ( RAD001 ), an mTOR inhibitor , in relapsed MCL patients have reported a significant response
Li et al., Toxicol Lett 2012 (MAP Kinase Signaling System) : Interestingly, taurine induced decreasing expression of LC3-II was partially blocked by pretreatment of RAD001 , an mTOR inhibitor
Józwiak et al., Future Oncol 2012 (Astrocytoma...) : Everolimus ( RAD001 ), a mTOR inhibitor , was initially used as an immunosuppressant in organ transplant patients ; however, it also has significant antineoplastic properties
Park et al., Leukemia 2013 (Leukemia, Myeloid, Acute...) : We conducted a phase Ib trial combining RAD001 ( everolimus ), an allosteric inhibitor of mTORC1 , and conventional chemotherapy, in AML patients under 65 years of age at first relapse ( clinical trial NCT 01074086 )
Nassim et al., PloS one 2013 (Urinary Bladder Neoplasms) : Clonogenic assays were performed using 6 bladder cancer cell lines ( UM-UC3, UM-UC5, UM-UC6, KU7, 253J-BV, and 253-JP ) in order to examine the effects of ionizing radiation ( IR ) alone and in combination with RAD001 , an mTOR inhibitor